Sex and the Kidney Drug-Metabolizing Enzymes and Transporters: Are Preclinical Drug Disposition Data Translatable to Humans?
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
06 May 2024
06 May 2024
Historique:
received:
18
12
2023
accepted:
06
04
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
7
5
2024
Statut:
aheadofprint
Résumé
Cross-species differences in drug transport and metabolism are linked to poor translation of preclinical pharmacokinetic and toxicology data to humans, often resulting in the failure of new chemical entities (NCEs) during clinical drug development. Specifically, inaccurate prediction of renal clearance and renal accumulation of NCEs due to differential abundance of enzymes and transporters in kidneys can lead to differences in pharmacokinetics and toxicity between experimental animals and humans. We carried out liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based protein quantification of 78 membrane drug-metabolizing enzymes and transporters (DMETs) in the kidney membrane fractions of humans, rats, and mice for characterization of cross-species and sex-dependent differences. In general, majority of DMET proteins were higher in rodents than in humans. Significant cross-species differences were observed in 30 out of 33 membrane DMET proteins quantified in all three species. Although no significant sex-dependent differences were observed in humans, the abundance of 28 and 46 membrane proteins showed significant sex dependence in rats and mice, respectively. These cross-species and sex-dependent quantitative abundance data are valuable for gaining a mechanistic understanding of drug renal disposition and accumulation. Further, these data can also be integrated into systems pharmacology tools, such as physiologically based pharmacokinetic models, to enhance the interpretation of preclinical pharmacokinetic and toxicological data.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Organisme : National Institutes of Health, , USA
ID : R01.HD081299
Informations de copyright
© 2024 The Authors. Clinical Pharmacology & Therapeutics © 2024 American Society for Clinical Pharmacology and Therapeutics.
Références
Nigam, S.K., Wu, W., Bush, K.T., Hoenig, M.P., Blantz, R.C. & Bhatnagar, V. Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clin. J. Am. Soc. Nephrol. 10, 2039–2049 (2015).
Kohler, J.J. et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab. Invest. 91, 852–858 (2011).
Al‐Majdoub, Z.M. et al. Quantitative proteomic map of enzymes and transporters in the human kidney: stepping closer to mechanistic kidney models to define local kinetics. Clin. Pharmacol. Ther. 110, 1389–1400 (2021).
Basit, A. et al. Characterization of differential tissue abundance of major non‐CYP enzymes in human. Mol. Pharm. 17, 4114–4124 (2020).
Lolkema, M.P. et al. The c‐Met tyrosine kinase inhibitor JNJ‐38877605 causes renal toxicity through species‐specific insoluble metabolite formation. Clin. Cancer Res. 21, 2297–2304 (2015).
Moriwaki, Y., Yamamoto, T., Takahashi, S., Tsutsumi, Z. & Hada, T. Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. Histol. Histopathol. 16, 745–753 (2001).
Smith, D.A. & Obach, R.S. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem. Res. Toxicol. 22, 267–279 (2009).
Wang, L. et al. Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics. Drug Metab. Dispos. 43, 367–374 (2015).
Tang, H. & Mayersohn, M. Controversies in allometric scaling for predicting human drug clearance: an historical problem and reflections on what works and what does not. Curr. Top. Med. Chem. 11, 340–350 (2011).
Zou, P. et al. Applications of human pharmacokinetic prediction in first‐in‐human dose estimation. AAPS J. 14, 262–281 (2012).
Han, J.J. FDA Modernization Act 2.0 allows for alternatives to animal testing. Artif. Organs 47, 449–450 (2023).
McDonough, A.A., Harris, A.N., Xiong, L. & Layton, A.T. Sex differences in renal transporters: assessment and functional consequences. Nat. Rev. Nephrol. 20, 21–36 (2023).
Nematbakhsh, M. et al. Gender difference in cisplatin‐induced nephrotoxicity in a rat model: greater intensity of damage in male than female. Nephrourol. Mon. 5, 818–821 (2013).
Sharma, S., Mettu, V.S. & Prasad, B. Interplay of breast cancer resistance protein (Bcrp/Abcg2), sex, and fed state in oral pharmacokinetic variability of furosemide in rats. Pharmaceutics 15, 542 (2023).
Sekine, T., Cha, S.H. & Endou, H. The multispecific organic anion transporter (OAT) family. Pflugers Arch. 440, 337–350 (2000).
Hazelhoff, M.H., Bulacio, R.P. & Torres, A.M. Gender related differences in kidney injury induced by mercury. Int. J. Mol. Sci. 13, 10523–10536 (2012).
Li, C.Y., Hosey‐Cojocari, C., Basit, A., Unadkat, J.D., Leeder, J.S. & Prasad, B. Optimized renal transporter quantification by using aquaporin 1 and aquaporin 2 as anatomical markers: application in characterizing the ontogeny of renal transporters and its correlation with hepatic transporters in paired human samples. AAPS J. 21, 88 (2019).
Demichev, V., Messner, C.B., Vernardis, S.I., Lilley, K.S. & Ralser, M. DIA‐NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17, 41–44 (2020).
Wiśniewski, J.R. & Rakus, D. Quantitative analysis of the Escherichia coli proteome. Data Brief 1, 7–11 (2014).
Sharma, S. et al. Quantitative characterization of clinically relevant drug‐metabolizing enzymes and transporters in rat liver and intestinal segments for applications in PBPK modeling. Mol. Pharm. 20, 1737–1749 (2023).
Horner, S., Ryan, D., Robinson, S., Callander, R., Stamp, K. & Roberts, R.A. Target organ toxicities in studies conducted to support first time in man dosing: an analysis across species and therapy areas. Regul. Toxicol. Pharmacol. 65, 334–343 (2013).
Craveiro, N.S., Lopes, B.S., Tomás, L. & Almeida, S.F. Drug withdrawal due to safety: a review of the data supporting withdrawal decision. Curr. Drug Saf. 15, 4–12 (2020).
Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56–67 (2000).
Greaves, P., Williams, A. & Eve, M. First dose of potential new medicines to humans: how animals help. Nat. Rev. Drug Discov. 3, 226–236 (2004).
Fagerholm, U. Prediction of human pharmacokinetics — renal metabolic and excretion clearance. J. Pharm. Pharmacol. 59, 1463–1471 (2010).
Mahmood, I. Interspecies scaling: predicting volumes, mean residence time and elimination half‐life. Some suggestions. J. Pharm. Pharmacol. 50, 493–499 (2011).
Walton, K., Dorne, J.L.C.M. & Renwick, A.G. Species‐specific uncertainty factors for compounds eliminated principally by renal excretion in humans. Food Chem. Toxicol. 42, 261–274 (2004).
Leusch, A., Troger, W., Greischel, A. & Roth, W. Pharmacokinetics of the M1‐agonist talsaclidine in mouse, rat, rabbit and monkey, and extrapolation to man. Xenobiotica 30, 797–814 (2000).
Lavé, T. et al. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J. Pharm. Pharmacol. 51, 85–91 (2010).
Chen, Y., Zhang, S., Sorani, M. & Giacomini, K.M. Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J. Pharmacol. Exp. Ther. 322, 695–700 (2007).
Li, Q., Peng, X., Yang, H., Wang, H. & Shu, Y. Deficiency of multidrug and toxin extrusion 1 enhances renal accumulation of paraquat and deteriorates kidney injury in mice. Mol. Pharm. 8, 2476–2483 (2011).
Damme, K., Nies, A.T., Schaeffeler, E. & Schwab, M. Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. Drug Metab. Rev. 43, 499–523 (2011).
Fisel, P., Renner, O., Nies, A.T., Schwab, M. & Schaeffeler, E. Solute carrier transporter and drug‐related nephrotoxicity: the impact of proximal tubule cell models for preclinical research. Expert Opin. Drug Metab. Toxicol. 10, 395–408 (2014).
Diamond, S., Boer, J., Maduskuie, T.P. Jr., Falahatpisheh, N., Li, Y. & Yeleswaram, S. Species‐specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab. Dispos. 38, 1277–1285 (2010).
Bleasby, K. et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre‐clinical species: a resource for investigations into drug disposition. Xenobiotica 36, 963–988 (2006).
Basit, A., Radi, Z., Vaidya, V.S., Karasu, M. & Prasad, B. Kidney cortical transporter expression across species using quantitative proteomics. Drug Metab. Dispos. 47, 802–808 (2019).
Omote, H., Hiasa, M., Matsumoto, T., Otsuka, M. & Moriyama, Y. The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol. Sci. 27, 587–593 (2006).
Chu, X., Bleasby, K. & Evers, R. Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin. Drug Metab. Toxicol. 9, 237–252 (2013).
Urakami, Y. et al. Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett. 461, 339–342 (1999).
Filipski, K.K., Mathijssen, R.H., Mikkelsen, T.S., Schinkel, A.H. & Sparreboom, A. Contribution of organic cation transporter 2 (OCT2) to cisplatin‐induced nephrotoxicity. Clin. Pharmacol. Ther. 86, 396–402 (2009).
Ljubojević, M. et al. Renal expression of organic anion transporter OAT2 in rats and mice is regulated by sex hormones. Am. J. Physiol. Renal Physiol. 292, F361–F372 (2007).
Kudo, N., Katakura, M., Sato, Y. & Kawashima, Y. Sex hormone‐regulated renal transport of perfluorooctanoic acid. Chem. Biol. Interact. 139, 301–316 (2002).
Sabolić, I., Asif, A.R., Budach, W.E., Wanke, C., Bahn, A. & Burckhardt, G. Gender differences in kidney function. Pflugers Arch. 455, 397–429 (2007).
Huang, K.‐C. & Mcintosh, B.J. Effect of sex hormones on renal transport of p‐aminohippuric acid. Am. J. Physiol. Legacy Content 183, 387–390 (1955).
Ljubojević, M. et al. Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibition. Am. J. Physiol. Renal Physiol. 287, F124–F138 (2004).
Sakemi, T., Ohtsuka, N., Tomiyoshi, Y. & Morito, F. Sex difference in progression of adriamycin‐lnduced nephropathy in rats. Am. J. Nephrol. 16, 540–547 (1996).
Ji, L., Masuda, S., Saito, H. & Inui, K.‐I. Down‐regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int. 62, 514–524 (2002).
Urakami, Y., Okuda, M., Saito, H. & Inui, K. Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Lett. 473, 173–176 (2000).
Yamazaki, M. et al. In vitro substrate identification studies for p‐glycoprotein‐mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther. 296, 723–735 (2001).
Baltes, S., Gastens, A.M., Fedrowitz, M., Potschka, H., Kaever, V. & Löscher, W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P‐glycoprotein. Neuropharmacology 52, 333–346 (2007).